S. Koreans' happiness rising slowly but surely: presidential panel
No. of depression patients exceeds 1m in 2022
Races tighten in Seoul as parties battle for Assembly control
Seoul subway fare to rise 12% beginning Saturday
Korean Air to submit new merger plan to ease antitrust concerns
US calls on China to encourage N. Korea's return to diplomacy
US House votes to remove Speaker Kevin McCarthy
6-year-old Uzbek girl found dead in Daegu
22 Chinese apprehended after illegal entry attempt
Hyundai Ioniq 7 may start production in July next year
Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLCBy PRNEWSWIRE
Published : May 31, 2023 - 15:10
SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'. The total contract size is 325 million dollars, and it includes an upfront payment of 1.9 million dollars and milestone payments according to future development, permits, and sales.
JIN-A04 is an oral TKI targeting non-small cell lung cancer carrying HER2 mutations, and there is currently no approved oral drug approved to date. Preclinical data of JIN-A04 was recently presented at the 2023 edition of the American Cancer Research Association (AACR) annual meeting in April at Orlando, USA showing strong efficacy in both In-vitro and In-vivo studies.
Yuhan Corporation CEO, Wook-Je Cho said, "We have taken a step forward in the development of the 2nd and 3rd LECLAZA by securing an additional anti-cancer drug pipeline with this contract. We plan to further strengthen our anticancer drug pipeline in the future."
Anna Jo, CEO of J INTS BIO, said, "JIN-A04 is expected to be a hope for NSCLC patients with 'HER2 Exon20 insertion' mutations." And it can become the most promising Best-in-Class TKI therapy in this field."
Meanwhile, Yuhan invested 1.5 million dollars in J INTS BIO in 2021 and 2022, respectively, and holds a 14.8% stake in the company.
Korea to begin experiment with central bank digital currency
Defense Ministry warns NK regime over nuclear buildup
PM orders measures to prevent public opinion manipulation on web portals